Therapeutic Advances in Retinal RNA Delivery

Abstract

Recent years have witnessed significant progress in the field of retinal RNA delivery, offering promising therapeutic avenues for various inherited and acquired retinal disorders. The precision and versatility of RNA-based therapeutics, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and messenger RNA (mRNA), have enabled targeted modulation of gene expression, paving the way for innovative treatments that address the root cause of retinal diseases. This review synthesizes current scientific literature and clinical trial data to provide healthcare professionals with an up-to-date overview of the epidemiology, pathophysiology, risk factors, clinical manifestations, diagnostic modalities, and, most importantly, the therapeutic advances in retinal RNA delivery. We discuss the mechanism of action of RNA-based agents, delivery platforms, recent breakthroughs, practical clinical implications, and expert perspectives on future directions in this rapidly evolving field.

Introduction

The retina, a highly specialized neural tissue responsible for phototransduction, is susceptible to a range of degenerative, inflammatory, and vascular pathologies. Genetic mutations and dysregulated gene expression underlie many blinding retinal conditions, including retinitis pigmentosa, age-related macular degeneration (AMD), and inherited retinal dystrophies. Conventional treatments have often been palliative, failing to address the molecular drivers of disease. RNA-based therapeutics offer the potential to silence, replace, or modify aberrant gene expression, enabling personalized and disease-modifying interventions. This review explores the scientific rationale, clinical evidence, and therapeutic landscape of retinal RNA delivery, with a focus on mechanisms, efficacy, safety, and practical application in clinical ophthalmology.

Epidemiology / Disease Burden

Inherited retinal diseases (IRDs) collectively affect approximately 1 in 3,000 individuals globally. Age-related macular degeneration remains a leading cause of irreversible vision loss in individuals over 60, with an estimated 200 million affected worldwide. Diabetic retinopathy and retinal vein occlusion further contribute to the global disease burden, underscoring the need for innovative molecular therapies. Many of these disorders are genetically heterogeneous, complicating conventional therapeutic strategies and highlighting the appeal of gene and RNA-based interventions to target specific genetic defects or pathogenic transcripts.

Pathophysiology

The pathophysiology of retinal diseases is complex and frequently involves genetic mutations that disrupt normal retinal structure and function. In IRDs, mutations in genes encoding photoreceptor proteins or components of the visual cycle lead to progressive photoreceptor degeneration. In AMD and diabetic retinopathy, dysregulated angiogenesis, inflammation, and oxidative stress play central roles. RNA-based therapeutics can selectively downregulate pathogenic transcripts (via siRNA or ASO), correct splicing defects, or introduce functional proteins (via mRNA), thus directly modulating disease pathways at the molecular level.

Risk Factors

Genetic predisposition is the primary risk factor for IRDs, with over 250 causative genes identified. For conditions like AMD and diabetic retinopathy, environmental factors such as age, smoking, hypertension, hyperglycemia, and dyslipidemia also contribute. Understanding genotype-phenotype correlations is crucial for patient selection and optimizing therapeutic outcomes with RNA-based interventions.

Clinical Features

Symptoms of retinal diseases vary based on etiology but commonly include progressive vision loss, night blindness, photophobia, central or peripheral scotomas, and color vision deficits. Clinical examination may reveal pigmentary changes, vascular abnormalities, retinal atrophy, or neovascularization. Early identification of disease-specific features aids in timely intervention and suitability assessment for RNA-based therapies.

Diagnosis

Diagnosis relies on detailed ophthalmic examination, multimodal imaging (fundus photography, optical coherence tomography, fluorescein angiography), and increasingly, genetic testing. Next-generation sequencing panels enable comprehensive molecular diagnosis, critical for identifying candidates for RNA-based therapy and for monitoring therapeutic response.

Treatment & Management

Traditional management of retinal diseases has involved vitamin supplementation, anti-VEGF agents, corticosteroids, laser therapy, and, in select cases, gene replacement via viral vectors. While these approaches provide symptomatic relief or disease stabilization, they rarely address underlying genetic or molecular defects. The emergence of RNA therapeutics enables selective silencing (e.g., siRNA for VEGF in AMD), splicing modification (e.g., ASOs in Leber congenital amaurosis), or protein replacement (mRNA therapy). Optimizing delivery to retinal cells remains a key challenge, with current strategies including intravitreal, subretinal, and suprachoroidal injections, as well as nanoparticle-mediated and viral vector-based delivery systems.

Recent Advances / Emerging Therapies

Several RNA-based therapies have reached clinical trials or received regulatory approval. The ASO voretigene neparvovec (for RPE65 mutation-associated retinal dystrophy) and the investigational QR-110 (sepofarsen) for CEP290-associated Leber congenital amaurosis illustrate the clinical translation of RNA technology. siRNA therapies targeting VEGF and other angiogenic factors are in advanced stages of development for neovascular AMD and diabetic retinopathy. Recent breakthroughs in lipid nanoparticle and exosome-based delivery systems have improved RNA stability and cellular uptake, minimizing immunogenicity and off-target effects. Preclinical studies suggest that CRISPR/Cas9-mediated RNA editing and RNA aptamers could further expand the therapeutic toolbox. Safety profiles are generally favorable, although long-term data are needed.

Guideline Recommendations

Expert consensus and emerging guidelines recommend genetic testing for patients with suspected IRDs to enable precise molecular diagnosis and therapeutic eligibility. Multidisciplinary management involving genetic counselors, ophthalmologists, and molecular biologists is advocated. RNA-based therapies should be considered for eligible patients within clinical trials or approved protocols, with careful monitoring for adverse events and efficacy endpoints. Patient selection, informed consent, and post-therapy surveillance remain critical to optimizing outcomes and advancing the field responsibly.

Conclusion

The landscape of retinal therapeutics is being transformed by advances in RNA delivery, offering hope for durable, disease-modifying interventions for previously untreatable retinal disorders. Continued progress in delivery technologies, molecular targeting, and clinical trial outcomes will be pivotal in realizing the full potential of RNA-based therapies. Close collaboration between clinicians, researchers, and regulatory bodies is essential to translate these scientific advances into safe and effective clinical practice, ultimately improving vision and quality of life for patients with retinal disease.